Chemical Component Summary

Nameamlodipine
Synonyms~{O}3-ethyl ~{O}5-methyl (4~{S})-2-(2-azanylethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
Identifiers~{O}3-ethyl ~{O}5-methyl (4~{S})-2-(2-azanylethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
FormulaC20 H25 Cl N2 O5
Molecular Weight408.876
TypeNON-POLYMER
Isomeric SMILESCCOC(=O)C1=C(NC(=C([C@@H]1c2ccccc2Cl)C(=O)OC)C)COCCN
InChIInChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3/t17-/m0/s1
InChIKeyHTIQEAQVCYTUBX-KRWDZBQOSA-N

Chemical Details

Formal Charge0
Atom Count53
Chiral Atom Count1
Bond Count54
Aromatic Bond Count6

Drug Info: DrugBank

DrugBank IDDB09237 
NameLevamlodipine
Groups
  • approved
  • investigational
DescriptionLevamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication.[L10833] Levamlodipine belongs to the dihydropyridine group of calcium channel blockers.[L10833] This medication was first marketed in Russia and India before being granted FDA approval.[L1484] The names S-amlodipine and levamlodipine may be used interchangeably as both substances are the same, however.[L10833] As a racemic mixture, amlodipine contains (R) and (S)-amlodipine isomers, but only (S)-amlodipine as the active moiety possesses therapeutic activity.[A188940] Levamlodipine was granted FDA approval on 19 December 2019.[L10833]
Synonyms
  • Levoamlodipine
  • Levamlodipine maleate
  • Levamlodipine
  • S-amlodipine
Brand Names
  • Conjupri
  • Levamlodipine
IndicationLevamlodipine is indicated alone or in combination to treat hypertension in adults and children.[L10833]
Categories
  • Antiarrhythmic agents
  • Antihypertensive Agents
  • Antihypertensive Agents Indicated for Hypertension
  • Calcium Channel Blockers
  • Cytochrome P-450 CYP3A Substrates
ATC-CodeC08CA17
CAS number103129-82-4

Drug Targets

NameTarget SequencePharmacological ActionActions
Voltage-dependent L-type calcium channel subunit alpha-1CMVNENTRMYIPEENHQGSNYGSPRPAHANMNANAAAGLAPEHIPTPGAAL...unknownantagonist
Voltage-dependent L-type calcium channel subunit alpha-1DMMMMMMMKKMQHQRQQQADHANEANYARGTRLPLSGEGPTSQPNSSKQTV...unknownantagonist
Nitric oxide synthase, endothelialMGNLKSVAQEPGPPCGLGLGLGLGLCGKQGPATPAPEPSRAPASLLPPAP...unknownagonist
Nitric oxide synthase, inducibleMACPWKFLFKTKFHQYAMNGEKDINNNVEKAPCATSSPVTQDDLQYHNLS...unknownagonist
Cytochrome P450 3A4MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...unknownsubstrate
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL2111097
PubChem 9822750
ChEMBL CHEMBL2111097
ChEBI CHEBI:53796
CCDC/CSD XOZRUZ